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Abstract Background: We deter-
mined the effects of two antibiotic
policies (predominance of either
b-lactam antibiotics or ﬂuroquinol-
ones) on acquisition with third-
generation cephalosporin-resistant
Enterobacteriaceae (CRE) and ﬂuor-
oquinolone-resistant CRE (FCRE) in
two ICUs, with monitoring of other
variables that may inﬂuence acquisi-
tion. Methods: After an 8-month
baseline period, units were random-
ized to a predominant b-lactam
antibiotic regimen (weekly cycling of
ceftriaxone, amoxicillin–clavulanic
acid and ﬂuroquinolones) or a ﬂuo-
roquinolone regimen for 3 months,
with cross-over for another 3 months.
Acquisition of CRE and FCRE was
determined by microbiological sur-
veillance. Results: During baseline,
acquisition rates for CRE and FCRE
were 14/1,000 and 2/1,000 patient
days at risk, respectively. Cross-
transmission of CRE accounted for
B25% of acquisitions, and CRE
acquisition was associated with the
use of b-lactam antibiotics (amoxi-
cillin–clavulanic acid in particular).
As compared to baseline, b-lactam
antibiotic use [in deﬁned daily dose
(DDD)/1,000 patient days] was
reduced from 854 to 526 (-39%) and
555 (-35%) during both intervention
periods. Fluoroquinolone use was
increased from 150 and 129 DDD/
1,000 patient days in baseline and the
b-lactam period to 514 DDD/1,000
patient days (?243%) in the ﬂuoro-
quinolone period. Reductions in
b-lactam use were not associated with
reduced CRE acquisition [adjusted
HRs were 1.0 (95% CR: 0.5–2.2) and
1.1 (95% CI: 0.5–2.5) during both
periods, respectively]. Increased use
of ﬂuoroquinolones was associated
with increased acquisition of FCRE
[adjusted HR 4.1 (95% CI: 1.4–11.9;
p\0.01]. Infection control variables
remained comparable during all
periods. Conclusion: A 35–39%
reduction of b-lactam exposure was
not associated with reduced acquisi-
tion of CRE, whereas a 243%
increase of ﬂuoroquinolone use
increased acquisition of FCRE.
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Introduction
Antimicrobial resistance is a serious and continuously
increasing threat to patient treatment worldwide. It is
obvious that antibiotic exposure contributes to the
emergence and spread of resistant pathogens, both in
hospitals and the community at large [1, 2]. Within
intensive care units (ICU) patients are frequently colo-
nized with antibiotic-resistant bacteria. Conversion of the
colonization status (i.e., from non-colonized to colonized)
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previously susceptible bacteria, (2) antibiotic-induced
selection of previously present, though undetectable,
resistant bacteria or (3) through patient-to-patient trans-
mission of pathogens (i.e., cross-transmission) [3]. Cross-
transmission is a multi-factorial process and depends on
patient characteristics, contact rates, stafﬁng and cohort-
ing levels of health-care workers (HCW), adherence to
hand hygiene, antibiotic use and colonization pressure
(i.e., proportion of patients colonized) [4]. The typically
small ICU patient populations (10–20 patients) and rapid
turnover create continuous ﬂuctuation of the prevalence
of resistant pathogens, hampering straightforward analy-
sis of interventions [5].
Data on the effects of modulation of antibiotic policies
on antibiotic resistance levels in ICUs are conﬂicting.
Antibiotic cycling has been advocated by some [6–8], but
positive ﬁndings were not conﬁrmed in other studies
[9, 10]. Importantly, confounding by unmeasured, but
potentially relevant, variables was not excluded in any of
these studies [5]. Therefore, we evaluated the effects of
a single antibiotic intervention on acquisition of coloni-
zation with third-generation cephalosporin-resistant
Enterobacteriaceae (CRE) in two ICUs. These bacteria
were chosen pragmatically, as prevalence rates of other
important antibiotic-resistant bacteria (i.e., methicillin-
resistant Staphylococcus aureus, vancomyin-resistant
enterococci, extended-spectrum b-lactamase producing
Enterobacteriaceae or carbapenem-resistant P. auerugin-
osa or Acinetobacter species) were very low and because
an easy screening method was available. In a baseline
period, CRE acquisition appeared to be predominantly of
endogenous origin (i.e., de novo resistance development
or selection) with the use of b-lactam antibiotics (amox-
icillin–clavulanic acid in particular) as a risk factor.
Therefore, a reduction of b-lactam use was pursued with
a homogeneous (ﬂuoroquinolones) antibiotic regimen,
which was compared to a cycling strategy (amoxicillin–
clavulanic acid, ceftriaxone and levoﬂoxacin) in a ran-
domized crossover study.
Patients and methods
Setting and study design
This study was conducted in two ICUs, a medical (MICU)
and neurosurgical ICU (NSICU), of the University Med-
ical Centre Utrecht, The Netherlands. The MICU has ten
beds,of which fourare inseparate rooms,and is situated in
the hospitals’ basement. The NSICU has eight beds, one in
a separate room, and is situated on the fourth ﬂoor. Med-
ical and nursing staffs are not shared between both ICUs.
During a baseline period of 8 months (9 September
2001 through 13 May 2002), colonization dynamics of
CRE were analyzed by means of microbiological
surveillance and genotyping, collection of demographical
and clinical data, and monitoring of infection control
practices. Based on the epidemiological ﬁndings obtained
during baseline (i.e., relative importance of acquisition
routes and risk factors for acquisition), an intervention
was designed to reduce the acquisition rate of CRE.
In a crossover design, reduction of b-lactam antibiotic
exposure (most notably amoxicillin–clavulanic acid and
ceftriaxone) was pursued by applying a homogeneous
(3 months) antibiotic policy for empirical treatment. This
strategy was compared to a cycling (3 months) period, in
which the ﬁrst choice antibiotic for empirical therapy
changed weekly from ceftriaxone in the 1st week, to
amoxicillin–clavulanic acid in the 2nd week, to levo-
ﬂoxacin or ciproﬂoxacin in the 3rd week, and back to
ceftriaxone in the 4th week, and so on. For individual
patients, antibiotics started, according to the weekly
schedule, were not adjusted when the weekly schedule
changed. During the homogenous regimen, levoﬂoxacin
or ciproﬂoxacin was the ﬁrst choice of empirical therapy.
The MICU was randomized to start with the cycling
regimen and the NSICU with the homogeneous regimen.
There were no wash-in/wash-out periods between differ-
ent study periods.
This study was approved by the institutional review
board, which waived the need of informed consent.
Data collection and microbiological surveillance
All patients admitted were included, and age, gender,
APACHE II score and admission indication were recor-
ded on admission. Antibiotic use was monitored
throughout the patients’ ICU stays. Collection of all
variables (demographics, antibiotic use, infection control
measures and microbiological data) was similar in all
three study periods.
Colonization with CRE was determined by means of
rectal swabs taken on admission and twice weekly
thereafter, plated on Chromogenic UTI agar plates (Oxoid
Limited, Basingstoke, UK) supplemented with 8 lg/ml
cefpodoxime and 6 lg/ml vancomycin. Species identiﬁ-
cation of every morphological distinct colony was
performed using VITEK II (bioMe ´rieux, Lyon, France).
Resistance to third-generation cephalosporins was then
conﬁrmed by determination of the MIC values for
cefpodoxime and ceftazidime using Micronaut-S b-lac-
tamase III (Merlin Diagnostika GMBH, Bornheim-Hersel,
Germany). Isolates not resistant to either cefpodoxime or
ceftazidime, according to NCCLS guidelines [11], were
considered susceptible in further analyses. In addition,
susceptibility of CRE isolates to ciproﬂoxacin was
determined using microdilution susceptibility testing
according to NCCLS guidelines [11].
Colonization on admission was deﬁned as colonization
within the ﬁrst 48 h after ICU admission. Acquired
513colonization was deﬁned as colonization after 48 h of
ICU admission after a previous negative culture. The
primary end-point of analysis was number of acquisitions
per 1,000 patient days at risk (i.e., CRE acquisition rate).
Cross-transmission was deﬁned as acquired
colonization with genotypically related strains in epide-
miologically linked patients. CRE acquisitions not
fulﬁlling this deﬁnition were considered endogenous
acquisition, i.e., selection of pre-existing ﬂora or de novo
resistance development. Epidemiological linkage was
deﬁned as two patients having an overlap in ICU stay.
Becauseofthepossibilityoflow-levelcolonizationdirectly
after acquisition, a maximum time window (between dis-
charge and admission of ‘‘donor’’ and ‘‘acceptor’’ patients)
of 7 days was accepted [12]. CRE isolates were genotyped
by means of ampliﬁed fragment-length polymorphism
(AFLP) [13], and 80% similarity was used as the cutoff
point for genetic relatedness. Results of surveillance cul-
tures and genotyping were not available for the hospitals’
infection control department or ICU physicians.
Infection control practices
Observations of patients and nurses were used to determine
contact rates, cohorting levels of nursing staff and adher-
ence tohand hygiene. Cohorting is deﬁned as the likelihood
that after a previous contact, the next contact of a health-
care worker (HCW) is with the same patient [14]. Obser-
vations were performed by trained infection control nurses,
according to predetermined schedules (unknown to the ICU
staff), and were evenly distributed between 7 a.m. and
11 p.m. Twotypesof observations were performed—nurse-
oriented and patient-oriented observations—to calculate
contact rates, cohorting of nursing staff and adherence to
hand hygiene. Nurses were observed for 20 min, during
which the number of contacts and number of contacted
patients (nurse-patient contacts) were recorded, in order to
calculate contact rates and level of cohorting. Patients were
also observed for 20 min, during which number of contacts
(HCW–patient contacts), type of health-care worker (phy-
sician,nurse,physicaltherapist,radiologyassistant),typeof
contact, use and removal of gloves, and use and type of
hand hygiene were recorded, in order to determine contact
rates and adherence to hand hygiene.
A patient contact was deﬁned as any contact with a
patients’ skin or gown, irrespective of the duration or
intensity of contact. Contacts with other inanimate objects
were considered environmental. Gloves needed to be
removed and hand hygiene to be used before returning to
the communal environment of the ICU. Appropriate hand
hygiene was considered to be either washing hands with
soap and water or use of an alcoholic hand rub. Both ICUs
are provided with two sinks with both soap and alcohol
hand rub dispensers, with each bedside also having its
own alcohol hand rub dispenser.
Statistical and risk factor analysis
Continuous variables were analysed by Student’s t test or
Mann–Whitney U test and categorical variables by v
2 sta-
tistics. Acquisition rates (events per 1,000 patient days at
risk) were compared using a multivariate Cox proportional
hazard model, which controls for the time at risk, with
subsequent addition of potential confounders (all variables
with p\0.10). The model calculates hazard ratios (HR)
and95%conﬁdenceintervals.Allanalyseswereperformed
with SPSS software (SPSS Inc., Chicago, IL).
Results
Baseline
Patient characteristics, CRE colonization and infection
control
All analyses of the baseline period were performed sep-
arately for both ICUs. As no relevant differences (apart
from patient characteristics) were obtained, the combined
data of both wards are presented. During the 8-month
baseline period, 457 patients were admitted from which
1,243 cultures were obtained (Table 1). Thirty-three
patients (7.2%; 23 in MICU and 10 in NSICU) were
colonized with CRE on admission, and 44 patients (9.6%;
23 in MICU and 21 in MSICU) acquired colonization
during their stay in the ICU (Table 2). Origin of coloni-
zation (i.e., present on admission or acquired) could not
be determined for six patients, because cultures were
either taken more than 48 h after admission or patients
had been admitted before the start of the study period. The
CRE acquisition rate was 14/1,000 patient days at risk
with a mean time to acquisition of 7 days (Table 2).
Based on epidemiological linkage and genotyping, CRE
colonization was predominantly acquired endogenously:
11 of 44 (25%) cases of acquired colonization [5 of 23 in
MICU (21.7%) and 6 of 21 in NSICU (28.6%)] resulted
from cross-transmission. Therefore, the endogenous route
was considered the dominant route for acquired coloni-
zation. Of all patients colonized with CRE (n = 83), 16
(19%) were colonized with a ﬂuoroquinolone-resistant
isolate (FCRE): 9 on admission and 6 after acquisition of
FCRE in the ICU after a mean of 7 ± 10 days. The
acquisition rate of FCRE was 2.1/1,000 patient days.
In total, 352 nurse-patient contacts (nurse observa-
tions) and 435 HCW–patient contacts (patient
observations) were observed during 197 h (Table 3).
Nurses had 3.2 ± 1.3 patient contacts/h, and their level of
cohorting was 71% ± 22%. Patients received 4.0 ± 1.8
contacts/h from HCW (nurses, physicians, radiology
technicians, physical therapists). Adherence to hand
hygiene after patient contact was 55% overall, 59% for
physicians and 53% for nurses (p = 0.399) (Table 3).
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characteristics Variable Baseline Heterogeneous Homogeneous
Patient demographics
Patient days 3,818 1,281 1,176
Admitted patients 457 176 135
Age (years) 53 ± 19 57 ± 18 56 ± 15
APACHE II score 21 ± 82 3 ± 82 1 ± 7
MICU stay (days) 8 ± 11 7 ± 99 ± 10
Male sex [no. (%) of patients] 244 (53.4) 104 (59.1) 82 (60.7)
Mortality [no. (%)] 83 (18.2) 23 (13.6) 29 (21.5)
Admission indication
Cardiovascular 30 (6.6) 9 (5.1) 9 (6.7)
Pulmonary 94 (20.6) 36 (20.5) 34 (25.2)
Gastro-intestinal 10 (2.2) 4 (2.3) 0
Neurological 72 (15.8) 28 (15.9) 21 (15.6)
Sepsis 26 (5.7) 6 (3.4) 7 (5.2)
Trauma 45 (9.8) 14 (8.0) 5 (3.7)
Surgery 139 (30.4) 72 (40.9) 49 (36.3)
Other 41 (9.0) 7 (4.0) 10 (7.4)
Table 2 Colonization characteristics
Variable Period p-value*
Baseline Heterogeneous Homogeneous
Cephalosporin-resistant Enterobacteriaceae
Patients with CRE colonization (%) 83
a (18.2) 26 (14.8) 29 (21.5) 0.31/0.39
Patients with colonization on admission (%) 33 (7.2) 11 (6.3) 12 (8.9) 0.65/0.53
Patients with acquired colonization (%) 44 (9.6) 14 (8.0) 16 (11.9) 0.50/0.45
Acquisition rate/1,000 patient days at risk 14 14 18 0.95/0.69
Mean days to acquisition 7 ± 96 ± 77 ± 8 0.71/0.73
Ciproﬂoxacin-resistant CRE
Patients with ciproﬂoxacin-resistant CRE 16 (3.5) 4 (2.3) 11 (8.1) 0.43/0.02
Patients with ciproﬂoxacin-resistant CRE isolate on admission 9 (2.0) 1 (0.6) 1 (0.8) 0.30/0.47
Patients with acquired ciproﬂoxacin-resistant CRE isolate 6 (1.3) 3 (1.7) 8 (6.0) 0.71/\0.01
Mean days to acquisition 7 ± 10 7 ± 87 ± 8 0.98/0.47
Acquisition rate ciproﬂoxacin-resistant isolate/1,000 patient days 2.1 2.5 8.3 0.50/0.01
Origin of colonization (i.e., present on admission or acquired) could
not be determined for six patients, because cultures were either
taken more than 48 h after admission or patients had been admitted
before the start of the study period
a This includes four patients present in the unit at the time of study
onset
* Comparison of baseline versus heterogeneous/homogeneous
Table 3 Contact rates, compliance and cohorting
Variable Period p-value*
Baseline Heterogeneous Homogeneous
Observation of patients
No. of HCW–patient contacts 435 132 186
Contact rates of patients (contacts/h) 4.0 ± 1.8 2.9 ± 1.3 4.3 ± 2.5 0.01/0.70
Compliance (%) 55 57 53 0.77/0.73
Physicians (%) 59 63 43 0.75/0.28
Nurses (%) 53 55 58 0.73/0.42
Observation of nurses
No. of HCW–patient contacts 352 119 148
Contact rates nurses (contacts/h) 3.2 ± 1.3 2.5 ± 1.0 2.8 ± 1.4 0.02/0.28
Cohorted contacts (%) 71 ± 22 74 ± 23 74 ± 25 0.66/0.65
* Comparison of baseline versus heterogeneous/homogeneous
515Risk factors for acquisition with CRE during baseline
Inunivariateanalysis,CREacquisitionwasassociatedwith
a pulmonary admission indication, trauma, admission after
surgery and admission for ‘‘other’’ indications (Table 4).
Furthermore, all patients acquiring CRE had received
antibiotics, as compared to 63% of non-affected patients
(p\0.01). Amoxicillin–clavulanic acid and aminoglyco-
sides were associated with CRE acquisition. ICU ward,
APACHE II score, patient-speciﬁc contact rates and hand
hygienewerenotassociatedwithCRE acquisition.Forthis
analysis,handhygieneandcontactrateswerecalculatedon
the patient-level instead of using the means of each period.
In multivariate analysis, admission because of trauma
remained independently associated with CRE acquisition
[hazard ratio (HR): 2.7, CI: 1.1–6.6].
In summary, acquired colonization with CRE pre-
dominantly occurred endogenously (75% of acquisitions),
and amoxicillin–clavulanic acid and ceftriaxone accoun-
ted for 62% of antibiotic exposure. Based upon this
ﬁnding and reported associations of b-lactam use and
acquisition of gram-negatives resistant to these antibiotics
[15, 16], we hypothesized that reducing b-lactam antibi-
otic use would decrease CRE acquisition rates.
Intervention period
During the intervention periods, patient characteristics
were comparable to baseline (Table 1). Again, all analy-
ses were performed ﬁrst for both ICUs separately with
similar results (data not shown). As there were no relevant
demographic differences between the wards (apart from
indication of admission) and intervention effects were
comparable, data are combined. In all, 421 and 376 cul-
tures were obtained during the heterogeneous and
homogeneous period, respectively. Percentages of
patients colonized on admission with CRE or FCRE were
comparable in all three study periods (Table 2).
Antibiotic use
As compared to baseline, overall usage of antibiotics did
not change (Table 5). During baseline 67% of all patients
received antibiotics, as compared to 61 and 72% during
cycling and homogeneous study periods, respectively
(p = 0.12 and p = 0.33; data not shown). Yet, amoxi-
cillin–clavulanic acid use decreased from 37% of all
patients in baseline to 21% (p\0.01) and 16%
(p\0.01) during cycling and homogeneous periods,
respectively. Expressed in DDD/1,000 patient days, use of
amoxicillin–clavulanic acid was reduced from 326 in
baseline, to 131 in the cycling and 31 in the homogeneous
period, respectively. Ceftriaxone use during the cycling
regimen (19%, 130 DDD/1,000 patient days) was com-
parable to baseline (17%, 134 DDD/1,000 patient days),
but decreased to 10% of all patients (55 DDD/1,000
patient days) during the homogeneous regimen
(p\0.01). Naturally, other b-lactam antibiotics (i.e.,
ceftazidime, piperacillin–tazobactam and carbapenems)
were needed for speciﬁc treatment indications, and their
need increased by 19% during the homogeneous period.
Therefore, total use of b-lactam antibiotics was reduced
by 39 and 35% in the cycling and homogeneous periods,
respectively. Fluoroquinolone use slightly decreased in
the cycling period (150 vs 129 DDD/1,000 patient days in
the baseline and heterogeneous period, respectively),
Table 4 Risk factors for CRE acquisition
Variable Without CRE Acquired CRE p-value HR 95% CI interval p-value
(n = 374) (n = 44)
Demographics
Age 54 ± 18 55 ± 18 0.81
Male sex 195 (52%) 26 (59%) 0.38
APACHE II score 21 ± 82 2 ± 6 0.58
MICU 229 (61%) 23 (52%) 0.25
Contact rate 4.6 ± 3.1 5.5 ± 3.6 0.22
Hand hygiene 47% ± 41% 53% ± 39% 0.59
Admission diagnoses
Pulmonary disease 66 (18%) 15 (34%) 0.01 2.10 0.88–5.03 0.09
Cardiovascular disease 24 (6%) 1 (2%) 0.27
Neurological disease 62 (17%) 5 (11%) 0.37
Trauma 30 (8%) 14 (32%) \0.01 2.71 1.11–6.61 0.03
Surgery 124 (32%) 6 (14%) 0.01 1.50 0.52–4.35 0.45
Other 68 (18%) 3(7%) 0.06 1.45 0.18–11.91 0.73
Antibiotic therapy 237 (63%) 44 (100%) \0.01
Amoxicillin–clavulanic acid 127 (34%) 32 (73%) \0.01 1.49 0.70–3.14 0.30
Ceftriaxone 57 (15%) 8 (18%) 0.61
Aminoglycosides 71 (19%) 22 (50%) \0.01 0.97 0.50–1.90 0.93
Quinolones 28 (8%) 5 (11%) 0.37
516although proportions of patients being exposed slightly
increased (from 8% during baseline to 13% in the heter-
ogeneous period (p = 0.07). In the homogeneous period,
51% of all patients received ﬂuorquinolones, yielding a
total exposure of 514 DDD/1,000 patient days (?243% as
compared to baseline).
Infection control
Contact rates received by patients were lowest during the
cycling period, 2.9 ± 1.3, as compared to 4.0 ± 1.8
(p = 0.01) during baseline and 4.3 ± 2.5 (p = 0.02)
during the homogeneous period (Table 3). The contact
rates of nurses were also lowest during the cycling period:
2.5 ± 1.0, as compared to 3.2 ± 1.3 (p = 0.02) during
baseline and 2.8 ± 1.4 (p = 0.28) during the homoge-
neous period. Adherence to hand hygiene and cohorting
levels were comparable during all three study periods.
Acquisition rates
Acquisition rates of CRE were 14/1,000 and 18/1,000
patient days at risk during the cycling and homogenous
period, respectively (as compared to 14/1,000 patient days
at risk in baseline). In a Cox proportional hazards model
(using baseline as reference), with adjustment for ICU,
age, APACHE II score, admission indication and contact
rates, acquisition was comparable in all three study peri-
ods (adjusted HR: 1.0, 95% CI: 0.5–2.2; p = 0.95 for the
cycling regimen and adjusted HR: 1.1, 95% CI: 0.5–2.5;
p = 0.69 for the homogeneous regimens).
Acquisition rates FCRE were 2.1 and 2.5/1,000 patient
days at risk in the baseline and cycling period, respec-
tively, and increased to 8.3/1,000 patient days at risk
during the homogeneous period. The adjusted HR (using
the same variables for adjustment) was 4.1 (95% CI: 1.4–
11.9; p\0.01). Seventeen patients acquired colonization
with FCRE. Five patients had acquired isolates that were
genotypically related and epidemiologically linked to
those of other patients (one during the cycling period and
four during the homogeneous period). The remaining 12
patients either did not have epidemiological linkage or
acquired colonization with other genotypes, and thus,
acquired colonization via the endogenous route.
Discussion
In this study, we evaluated the effects of two empiric
antibiotic regimens on acquisition of third-generation
cephalosporin-resistant Enterobacteriaceae (CRE) and
ﬂuoroquinolone-resistant CRE (FCRE) in two ICUs.
Based on the relevance of endogenous acquisition of
colonization and the predominant use of amoxicillin–
clavulanic acid and ceftriaxone use (62% of total antibi-
otic use) in a baseline period, a step-wise reduction of
amoxicillin–clavulanic acid use (of 60 and 91%) and
ceftriaxone use (of 3 and 59%), at the costs of increased
usage of ﬂuoroquinolones (?243% in the homogeneous
period), failed to reduce CRE acquisition, but signiﬁ-
cantly increased acquisition of FCRE.
A strength of our study is that it is the ﬁrst to use
prospective surveillance of colonization, large-scale
genotyping, a baseline period to determine colonization
dynamics and accurate monitoring of multiple variables
that might inﬂuence colonization dynamics. Although
AFLP is not the most widely used genotyping method, it
has similar discriminatory power as pulsed-ﬁeld gel-
electrophoresis and multi-locus sequence typing for both
gram-positive and gram-negative bacteria [17, 18]. As
only few studies have monitored antibiotic use in DDD/
1,000 patient days, contact rates, cohorting levels and
adherence to hand hygiene, comparison to other ICUs is
difﬁcult.
Table 5 Antibiotic use during study periods
Baseline Heterogeneous Homogeneous
n = 457 n = 176 n = 135
No. of patients receiving antibiotics 306 (67%) 107 (61%) 97 (72%)
No. of DDD/1,000 patient days (%D to baseline) (%D to baseline)
Amoxicillin–clavulanic acid 326 131 (-60%)* 31 (-91%)*
Ceftriaxone 134 130 (-3%) 55 (-59%)*
Ceftazidime 21 29 (?38%) 9 (-57%)
Piperacillin-tazobactam 38 9 (-74%) 10 (-74%)
Carbapenems 52 60 (?15%) 96 (?54%)
Other beta-lactam antibiotics
a 283 167 (-41%) 354 (?25%)
Total beta-lactam antibiotics 854 526 (-39%) 555 (-35%)
Aminiglycosides 159 142 (-11%) 91 (-43%)*
Quinolones 150 129 (-14%) 514 (?243%)*
DDD deﬁned daily dosage
a Amoxicillin, ﬂucloxacillin, piperacillin
* p\0.05 as compared to baseline
517Total antibiotic use in our ICUs (1,380 DDD/1,000
patient days in our ICU) was comparable to German ICUs
(on average 1,332 DDD/1,000 patient days) participating
in the project Surveillance of Antimicrobial Use and
Antimicrobial Resistance in ICUs (SARI) [19]. And dis-
tribution of antibiotic classes in our setting corresponded
to the average of 53 ICUs in non-university acute care
hospitals in Southern Germany, where beta-lactams and
ﬂuoroquinolones accounted for 59 and 11% of total use
(61 and 8% in our ICUs) [20].
In our study the number of contacts received by an indi-
vidual patient per hour ranged from 0 to 9 contacts/h, which
wouldyield0–72contacts/hunit-widewith100%occupancy.
This is similar to contact rates reported by others [21, 22].
Slightlylower(15/hforawholeICU))andhigher(6.6/patient/
h) contact rates, though, have been reported as well [23, 24].
ReportedcohortinglevelsofnursesinICUshaverangedfrom
70 to 77% [21, 24, 25], which is fairly similar to the 71–74%
that we observed. Most information is available on adherence
to hand hygiene. Using different monitoring strategies,
reportedadherenceratesinICUshaverangedfrom12to81%,
but usually do not exceed 50% [26, 27]. Although still not
optimal,adherencerates,asobservedinourstudy,appearedto
be above average, which might explain the low incidence of
cross-transmission in the baseline period. For all these rea-
sons,weconsiderourunitsasrathergeneralizablewithregard
to antibiotic use and infection control practices.
There are also several limitations of our study that
must be addressed. The ﬁrst limitation is related to the
complexity of patient care in ICUs. With all efforts, we
were only able to reduce overall b-lactam antibiotic use
by 35–39%. These antibiotics are considered optimal
treatment for many indications, and need for them of
course overruled the study protocol. Therefore, further
reductions in b-lactam antibiotic exposure may not be
feasible. Furthermore, for logistical reasons we only
obtained rectal swabs, and not respiratory or environ-
mental samples. Although the rectum is the most
important colonization site for CRE, we may have missed
some patients that were only colonized in the respiratory
tract. And in contrast to, for instance, enterococci, there
is no evidence that environmental contamination is
important in the epidemiology of multi-resistant Entero-
bacteriaceae. In addition, we used intestinal colonization
as endpoint, and we did not collect information on CRE
infections, or any other infections. Observations for
adherence to infection control measures were only per-
formed during daytime and not in nightly hours and
during weekends, and duration and intensity of contacts
were not monitored. Since there were no interventions
related to infection control measures, we assume that this
limitation had no effects. Finally, longer intervention
periods might have yielded different results. Yet, in the
absence of an environmental reservoir, the ecological
dynamics in an ICU are driven by patients who have a
short length of stay. In fact, the study periods were long
enough to document the increase in FCRE resistance.
Naturally, our ﬁndings are only generalizable to ICUs
using similar classes of antibiotics.
Our ﬁndings have demonstrated two important aspects
of antibiotic resistance in ICUs: (1) in two settings with
endemicity of resistance to b-lactam antibiotics, a
straightforward reduction of exposure to this antibiotic
class did not reduce prevalence levels of b-lactam resis-
tance; (2) in the absence of endemicity of ﬂuoroquinolone
resistance, increased exposure of this antibiotic class
increased ﬂuoroquinolone resistance. These ﬁndings
underscore the complexity of antibiotic resistance in
ICUs and the need to apply rigorous study designs when
evaluating interventions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
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